KevinNelsonHellerMD

Pediatric Hematology/Oncology

Executive Vice President, Research and Development

Dr. Heller is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

Office
9000 Virginia Manor Rd
Ste 200
Beltsville, MD 20705
Phone+1 240-479-2719

George Washington University School of Medicine and Health SciencesClass of 1998

PubMed

3 citations
Food increased the bioavailability of BMS-690514, an orally active EGFR/HER2/VEGF receptor kinase inhibitor, in healthy subjects.
Blisse Vakkalagadda, Jong-Soon Park, Christoph Matthias Ahlers, Stephanie M Dorizio, Teresa Has
Journal of Clinical Pharmacology. 2012-09-01
835 citations
Ipilimumab in patients with melanoma and brain metastases: An open-label, phase 2 trial
Kim Margolin, Marc S. Ernstoff, Omid Hamid, Donald P. Lawrence, David F. McDermott
The Lancet. Oncology. 2012-05-01
30 citations
Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma
Matthew M. Burke, Harriet M. Kluger, Marjorie Golden, Kevin N. Heller, Axel Hoos
Journal of Clinical Oncology. 2011-11-10

Jasper Therapeutics Announces New Clinical Trial with the National Institute of Allergy and Infectious Diseases to Evaluate JSP191 in Chronic Granulomatous DiseaseMay 26th, 2021
Making Stem Cell Transplants SaferApril 18th, 2021

Ebv-Specific T-Cells In Healthy Individuals And In Patients With EBV AssociatedNational Center For Research Resources2005
Ebv-Specific T-Cells In Healthy Individuals And EBVNational Center For Research Resources2004